U.S. markets close in 2 hours 5 minutes
  • S&P 500

    4,249.41
    -5.74 (-0.13%)
     
  • Dow 30

    34,319.48
    -74.27 (-0.22%)
     
  • Nasdaq

    14,087.43
    -86.71 (-0.61%)
     
  • Russell 2000

    2,317.99
    -8.16 (-0.35%)
     
  • Crude Oil

    71.94
    +1.06 (+1.50%)
     
  • Gold

    1,856.50
    -9.40 (-0.50%)
     
  • Silver

    27.70
    -0.34 (-1.21%)
     
  • EUR/USD

    1.2129
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.5020
    +0.0010 (+0.07%)
     
  • GBP/USD

    1.4082
    -0.0026 (-0.18%)
     
  • USD/JPY

    110.0830
    +0.0220 (+0.02%)
     
  • BTC-USD

    40,401.03
    +188.34 (+0.47%)
     
  • CMC Crypto 200

    1,005.87
    -4.74 (-0.47%)
     
  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Bank of America, Oracle and Nike

For Immediate Release

Chicago, IL – December 22, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (NYSE:PFE – Free Report), Microsoft (NASDAQ:MSFT – Free Report), Bank of America (NYSE:BAC – Free Report), Oracle (NYSE:ORCL – Free Report) and Nike (NYSE:NKE – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Stock Research Reports for Thursday

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (NYSE:PFE – Free Report), Microsoft (NASDAQ:MSFT – Free Report) and Bank of America (NYSE:BAC – Free Report).

Pfizer shares have gained +9.5% since results of the presidential election were declared on Nov 8, outperforming the Zacks Large-Cap Pharma industry which has gained +1.7% over the same period. While Pfizer in general and the industry as a whole continues to be weighed down by drug pricing worries, the issue has eased a bit since the election. The analyst emphasizes that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. A case in point is the Sep 2016 acquisition of Medivation that has strengthened Pfizer’s cancer franchise. Meanwhile, new products like Ibrance should do well and drive revenues. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. (You can read the full research report on Pfizer here>>>)

Buy rated Microsoft shares lagged the Zacks Tech sector through the fall, but have led the way over the last three months on greater appreciation for the company's reorganization and repositioning. Microsoft's 'cloud' opportunity particularly stands out, with the company generally considered as a leader in this fast-growing space alongside Amazon, Google and others. The Zacks analyst points to the company's continuing enterprise strength, benefits from the Office 365 subscription model, strong growth prospects of Azure and promising new products. Further, the anticipated completion of the LinkedIn acquisition will boost Microsoft's presence in the social media market. (You can read the full research report on Microsoft here>>>)

Buy rated Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election. This changed backdrop includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. The resulting uptrend in interest rates promises to give bank stocks in general and Bank of America in particular a big boost. No doubt, Bank of America share have been strong performers since the election - up +33.6% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period. (You can read the full research report on Bank of America here>>>)

Other noteworthy reports we are featuring today include Oracle (NYSE:ORCL – Free Report) and Nike (NYSE:NKE – Free Report). You can see all of today's analyst reports here >>>

Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on PFE - FREE

Get the full Report on MSFT - FREE

Get the full Report on BAC - FREE

Get the full Report on ORCL - FREE

Get the full Report on NKE - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PFIZER INC (PFE): Free Stock Analysis Report
 
MICROSOFT CORP (MSFT): Free Stock Analysis Report
 
BANK OF AMER CP (BAC): Free Stock Analysis Report
 
ORACLE CORP (ORCL): Free Stock Analysis Report
 
NIKE INC-B (NKE): Free Stock Analysis Report
 
To read this article on Zacks.com click here.